Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models

References

• Smith, Williams, Introduction to the Principles of Drug Design and Action, 4th Ed, USA: Taylor and Francis Group, 216-30.
   Google Scholar
• Rautio J, Kumpulainen H, Heimbach T, Oliyai R, Oh D, Jaervinen T, Savolainen J. Prodrugs: design and clinical applications. Nat Rev Drug Discov 2008; 7:255-70; PMID:18219308; http://dx.doi.org/10.1038/nrd2468
   PubMed Web of Science ®Google Scholar
• Huttunen KM, Raunio H, Rautio J: Prodrugs – from serendipity to rational design. Pharmacol Rev 2011; 63:750-71; PMID:21737530; http://dx.doi.org/10.1124/pr.110.003459
   PubMed Web of Science ®Google Scholar
• Stella VJ. Prodrugs: Some thoughts and current issues. J Pharm Sci 2010; 99:4755-65; PMID:20821387; http://dx.doi.org/10.1002/jps.22205
   PubMed Web of Science ®Google Scholar
• Brade WP, Herdrich K, Varini M. Ifosfamide- pharmacology, safety and therapeutic potential. Cancer Treat Rev 1985; 12:1-47; PMID:3896483; http://dx.doi.org/10.1016/0305-7372(85)90011-8
   PubMed Web of Science ®Google Scholar
• Dechant KL, Brogden RN, Pilkington T, Faulds D. Ifosfamide/Mesna: A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in Cancer. Drugs 1991; 42: 428-67; PMID: 1720382; http://dx.doi.org/10.2165/00003495-199142030-00006
   PubMed Web of Science ®Google Scholar
• Brade W, Seeber S, Herdrich K. Comparative activity of ifosfamide and cyclophosphamide. Cancer Chemother Pharmacol 1986; 18 (suppl 2): S1-S9; PMID:3545522; http://dx.doi.org/10.1007/BF00647438
   PubMedGoogle Scholar
• Boni C, Zanelli F. Ifosfamide in non-small cell lung cancer. Oncology 2003; 65 Suppl 2:50-4; PMID:14586148; http://dx.doi.org/10.1159/000073359
   PubMed Web of Science ®Google Scholar
• Denny WA. Prodrug strategies in cancer therapy. Eur J Med Chem 2001; 36:577-95; PMID:11600229; http://dx.doi.org/10.1016/S0223-5234(01)01253-3
   PubMed Web of Science ®Google Scholar
• Duan JX, Jiao H, Kaizerman J, Stanton T, Evans JW, Lan L, Lorente G, Banica M, Jung D, Wang J, Ma H, Li X, Yang Z, Hoffman RM, Ammons WS, Hart CP, Matteucci M. Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs. J Med Chem 2008; 51:2412-20; PMID:18257544; http://dx.doi.org/10.1021/jm701028q
   PubMed Web of Science ®Google Scholar
• Meng F, Evans JW, Bhupathi D, Banica M, Lan L, Lorente G, Duan JX, Cai X, Mowday AM, Guise CP, et al. Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302. Mol Cancer Ther 2012; 11:740-51; PMID:22147748; http://dx.doi.org/10.1158/1535-7163.MCT-11-0634
   PubMed Web of Science ®Google Scholar
• Sun JD, Liu Q, Wang J, Ahluwalia D, Ferraro D, Wang Y, Duan JX, Ammons WS, Curd JG, Matteucci MD, Hart CP. Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer. Clin Cancer Res 2012; 18:758-70; PMID:22184053; http://dx.doi.org/10.1158/1078-0432.CCR-11-1980
   PubMed Web of Science ®Google Scholar
• Liu Q, Sun JD, Wang J, Ahluwalia D, Baker AF, Cranmer LD, Ferraro D, Wang Y, Duan JX, Ammons WS, Curd JG, Matteucci MD, Hart CP. TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules. Cancer Chemother Pharmacol 2012; 69:1487-98; PMID:22382881; http://dx.doi.org/10.1007/s00280-012-1852-8
   PubMed Web of Science ®Google Scholar
• Hu J, Handisides DR, Van Valckenborgh E, De Raeve H, Menu E, Vande Broek I, Liu Q, Sun JD, Van Camp B, Hart CP, et al. Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug. Blood 2010; 116:1524-27; PMID:20530289; http://dx.doi.org/10.1182/blood-2010-02-269126
   PubMed Web of Science ®Google Scholar
• Chawla SP, Cranmer LD, Van Tine BA, Reed DR, Okuno SH, Butrynski JE, Adkins DR, Hendifar AE, Kroll S, Ganjoo KN. Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. J Clin Oncol 2014; 32:3299-306; PMID:25185097; http://dx.doi.org/10.1200/JCO.2013.54.3660
   PubMed Web of Science ®Google Scholar
• Borad MJ, Reddy SG, Bahary N, Uronis HE, Sigal D, Cohn AL, Schelman WR, Stephenson J Jr, Chiorean EG, Rosen PJ, et al. Randomized Phase II trial of gemcitabine plus TH-302 versus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2015; 33:1475-81; PMID:25512461; http://dx.doi.org/10.1200/JCO.2014.55.7504
   PubMed Web of Science ®Google Scholar
• Navada S, Lai P, Schwartz AG, Kalemkerian GP. Temporal trends in small cell lung cancer: analysis of the national Surveillance Epidemiology and End-Results (SEER) database [abstract 7082]. J Clin Oncol 2006; 24 (18S) suppl:384S
   Google Scholar
• Sher T, Dy GK, Adjei AA. Small cell lung cancer. Mayo Clin Proc 2008; 83:355-67; PMID:18316005; http://dx.doi.org/10.4065/83.3.355
   PubMed Web of Science ®Google Scholar
• Rosell R, Martin C, Balaña C. Ifosfamide in non-small-cell lung cancer. Ann Oncol 1999; 10 Suppl 5: S25-8; PMID:10582135; http://dx.doi.org/10.1093/annonc/10.suppl_5.S26
   PubMedGoogle Scholar
• Johnson DH. Overview of ifosfamide in small cell and non-small cell lung cancer. Semin Oncol 1990; 17:24-30; PMID:2159187; http://dx.doi.org/10.1016/0169-5002(91)90216-S
   PubMed Web of Science ®Google Scholar
• Vlahovic G, Infante JR, Mita AC, Traynor AM, Molina JR, Lacouture ME, Langmuir VK, Eng C, Kroll S, Borad MJ. Phase I/II study of TH-302 in combination with pemetrexed in patients with solid tumors including NSCLC [abstract]. J Clin Oncol 2010; 28 (15S) suppl: e13535
   Google Scholar
• Azrak RG, Cao S, Slocum HK, Tóth K, Durrani FA, Yin MB, Pendyala L, Zhang W, McLeod HL, Rustum YM. Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts. Clin Cancer Res 2004; 10:1121-9; PMID:14871992; http://dx.doi.org/10.1158/1078-0432.CCR-0913-3
   PubMed Web of Science ®Google Scholar
• Nagamachi Y, Tani M, Shimizu K, Tsuda H, Niitsu Y, Yokota J. Orthotopic growth and metastasis of human non-small cell lung carcinoma cell injected into the pleural cavity of nude mice. Cancer Lett 1998; 127:203-09; PMID:9619878 http://dx.doi.org/10.1016/s0304-3835(98)00039-1
   PubMed Web of Science ®Google Scholar
• Talmadge JE, Singh RK, Fidler IJ, Raz A. Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol. 2007; 170:793-804; PMID:17322365; http://dx.doi.org/10.2353/ajpath.2007.060929
   PubMed Web of Science ®Google Scholar
• Manzotti C, Audisio RA, Patresi G. Importance of orthotopic implantation for human tumors as model systems: relevance to metastasis and invasion. Clin Exp Metastasis 1993; 11:5-11; PMID:8422706; http://dx.doi.org/10.1007/BF00880061
   PubMed Web of Science ®Google Scholar
• Kerbel RS. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. Cancer Biol Ther 2003; 2: S134-9; PMID:14508091; http://dx.doi.org/10.4161/cbt.213
   PubMed Web of Science ®Google Scholar
• Inaba M, Tashiro T, Kobayashi T, Sakurai Y, Maruo K, Ohnishi Y, Ueyama Y, Nomura T. Responsiveness of human gastric tumors implanted in nude mice to clinically equivalent doses of various antitumor agents. Jpn J Cancer Res. 1988; 79:517-22; PMID: 3133340 http://dx.doi.org/10.1111/j.1349-7006.1988.tb01621.x
   PubMedGoogle Scholar
• Inaba M, Tashiro T, Kobayashi T, Sakurai Y, Maruo K, Ohnishi Y, Ueyama Y, Nomura T. Responsiveness of human gastric tumors implanted in nude mice to clinically equivalent doses of various antitumor agents. Jpn J Cancer Res 1988; 79:17-22; PMID:2833480; http://dx.doi.org/10.1111/j.1349-7006.1988.tb00005.x
   PubMedGoogle Scholar
• Inaba M, Kobayashi T, Tashiro T, Sakurai Y, Maruo K, Ohnishi Y, Ueyama Y, Nomura T. Evaluation of antitumor activity in a human breast tumor/nude mouse model with a special emphasis on treatment dose. Cancer 1989; 64:1577-82; PMID:2507122; http://dx.doi.org/10.1002/1097-0142(19891015)64:8%3c1577::AID-CNCR2820640803%3e3.0.CO;2-I
   PubMed Web of Science ®Google Scholar
• Tashiro T, Inaba M, Kobayashi T, Sakurai Y, Maruo K, Ohnishi Y, Ueyama Y, Nomura T. Responsiveness of human lung cancer/nude mouse to antitumor agents in a model using clinically equivalent doses. Cancer Chemother Pharmacol 1989; 24:187-92; PMID:2544308; http://dx.doi.org/10.1007/BF00300241
   PubMed Web of Science ®Google Scholar
• Inaba M, Kobayashi T, Tashiro T, Sakurai Y. Pharmacokinetic approach to rational therapeutic doses for human tumor-bearing nude mice. Jpn J Cancer Res 1988; 79:509-16; PMID:3133339; http://dx.doi.org/10.1111/j.1349-7006.1988.tb01620.x
   PubMedGoogle Scholar
• Segura C, Bandrés E, Trocóniz IF, García-Foncillas J, Sayar O, Dios-Vieítez C, Renedo MJ, Garrido MJ. Hematological response of topotecan in tumor-bearing rats: modeling of the time course of different cellular populations. Pharm Res 2004; 21:567-73; PMID:15139512; http://dx.doi.org/10.1023/B:PHAM.0000022402.00699.5c
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Aoki S, Mechinaud F, Bacher J, Lee J, Rubin M, Pizzo PA. Effects of preventive, early, and late antifungal chemotherapy with fluconazole in different granulocytopenic models of experimental disseminated candidiasis. J Infect Dis 1990; 161:755-60; PMID:2138654; http://dx.doi.org/10.1093/infdis/161.4.755
   PubMed Web of Science ®Google Scholar
• Dale DC, Cottle TE, Fier CJ, Bolyard AA, Bonilla MA, Boxer LA, Cham B, Freedman MH, Kannourakis G, Kinsey SE, et al. Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry. Am J Hematol 2003; 72:82-93; PMID:12555210; http://dx.doi.org/10.1002/ajh.10255
   PubMed Web of Science ®Google Scholar
• Weiss GJ, Infante JR, Chiorean EG, Borad MJ, Bendell JC, Molina JR, Tibes R, Ramanathan RK, Lewandowski K, Jones SF, et al. Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies. Clin Cancer Res 2011; 17:2997-300437; PMID:21415214; http://dx.doi.org/10.1158/1078-0432.CCR-10-3425
   PubMed Web of Science ®Google Scholar
• Hunter FW, Hsu HL, Su J, Pullen SM, Wilson WR, Wang J. Dual targeting of hypoxia and homologous recombination repair dysfunction in triple-negative breast cancer. Mol Cancer Ther 2014; 13:2501-1438; PMID:25193512; http://dx.doi.org/10.1158/1535-7163.MCT-14-0476
   PubMed Web of Science ®Google Scholar
• Kurowski V, Wagner T. Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy. Cancer Chemother Pharmacol 1993; 33:36-42; PMID:8269587; http://dx.doi.org/10.1007/BF00686020
   PubMed Web of Science ®Google Scholar
• Hureaux J, Lagarce F, Gagnadoux F, Rousselet MC, Moal V, Urban T, Benoit JP. Toxicological study and efficacy of blank and paclitaxel-loaded lipid nanocapsules after i.v. administration in mice. Pharm Res 2010; 27:421-30; PMID:20054705; http://dx.doi.org/10.1007/s11095-009-0024-y
   PubMed Web of Science ®Google Scholar